Nutritional Intervention for Age-related Muscular Function and Strength Losses

This study has been completed.
Sponsor:
Collaborators:
Iowa State University
South Dakota State University
Information provided by (Responsible Party):
Metabolic Technologies Inc.
ClinicalTrials.gov Identifier:
NCT00874575
First received: March 31, 2009
Last updated: September 16, 2014
Last verified: September 2014

March 31, 2009
September 16, 2014
November 2008
July 2013   (final data collection date for primary outcome measure)
Muscular Strength and functionality [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00874575 on ClinicalTrials.gov Archive Site
Bone turnover [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Nutritional Intervention for Age-related Muscular Function and Strength Losses
A Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D on Muscular Strength and Functionality in Older Adults.

The purpose of the study is to

  • Test the effect of a dietary supplement beta-hydroxy-beta-methylbutyrate (HMB) with and without Vitamin D to prevent and reverse the losses of muscular strength and functionality in older adults.

The second aim of the study is to determine if HMB and Vitamin D improves markers of bone turnover in adults aged 60 plus years. HMB is a dietary supplement that comes from the amino acid leucine. HMB is found in foods and is made in your body after you eat protein (meat). Subjects will be randomized to one of four dietary supplement groups and will participate in a 3-day per week exercise program for 12 weeks. Each exercise day will be about 60 minutes long consisting of strength training exercises utilizing Theraband® stretch cords and jumping.

Subjects will consume the dietary supplement 2 times per day for 12 weeks. Tests will consist of the following:

  • Measuring the strength of subjects' legs by using a Isokinetic Dynamometer
  • Measuring body composition
  • Measuring hand-grip strength using a hand-grip dynamometer
  • Measuring functional mobility, balance and agility by the time it takes for you to rise from a chair, walk around a cone 8 feet in front of the chair and return to the chair (Up-&-Go Test
  • Filling out questionnaires and having blood drawn for biochemical measurements. Testing will be performed at the beginning and at 4, 8 and 12 weeks.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Muscle Strength
  • Sarcopenia
  • Dietary Supplement: Placebo
  • Dietary Supplement: Vitamin D
    Other Name: Cholecalciferol
  • Dietary Supplement: Beta-hydroxy-Beta-methylbutyrate
    Other Name: HMB
  • Drug: Beta-hydroxy-Beta-methylbutyrate and Vitamin D
    Other Names:
    • Beta-hydroxy-Beta-methylbutyrate: HMB
    • Vitamin D: Cholecalciferol
  • Placebo Comparator: 1
    Control
    Intervention: Dietary Supplement: Placebo
  • Experimental: 2
    Beta-hydroxy-Beta-methylbutyrate, 3 g/d
    Intervention: Dietary Supplement: Beta-hydroxy-Beta-methylbutyrate
  • Experimental: 3
    Vitamin D, 2000 IU/d
    Intervention: Dietary Supplement: Vitamin D
  • Experimental: 4
    Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
    Intervention: Drug: Beta-hydroxy-Beta-methylbutyrate and Vitamin D
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
76
July 2013
July 2013   (final data collection date for primary outcome measure)

Subjects must meet all of the inclusion criteria in order to participate in the study.

  • Male and Female subjects will be enrolled into the study.
  • Age > 60 years.
  • Free of liver and kidney diseases, and with no evidence of uncontrolled hypertension.
  • Does not have a chronic disease that affects calcium or bone metabolism (i.e., asthma with chronic use of high dose steroids, inflammatory bowel disease, Crohn's disease, primary hyperparathyroidism, seizure disorder with use of phenobarbital, etc.).
  • Not classified as morbidly obese (body mass index (BMI) >40 kg/m2).
  • Six weeks since major surgery (three weeks since minor surgery).
  • Willing to consume one of the nutritional supplements for the study period.
  • Individuals diagnosed with osteoporosis (i.e., bone density > 2.5 standard deviations below the mean) will not be enrolled in the study.
  • No other serious medical illness.
  • Serum 25OH-VitD3 >10 and <25 ng/ml.
  • Able and willing to participate in 3-day-a-week monitored strength-training program.
  • Physician has placed no restriction on physical exercise.

All candidates meeting any one of the exclusion criteria will not be enrolled into the study and as necessary will be referred to their private physician for further follow-up.

  • Age < 60 years.
  • Evidence of liver and kidney diseases, uncontrolled hypertension, or Type I diabetes mellitus requiring insulin for glucose control.
  • Presence of a chronic disease that affects calcium or bone metabolism (i.e., asthma with chronic use of high dose steroids, inflammatory bowel disease, Crohn's disease, primary hyperparathyroidism, seizure disorder with use of phenobarbital, etc.).
  • Classified as morbidly obese (body mass index (BMI) >40 kg/m2).
  • Less than six weeks since major surgery or three weeks since minor surgery.
  • Not willing to consume one of the nutritional supplements for the study period.
  • Individuals diagnosed with osteoporosis (i.e., bone density > 2.5 standard deviations below the mean) will not be enrolled in the study.
  • Other serious medical illness, which the subjects doctor or medical review team has decided affects the subject's ability to participate in the study.
  • Subjects on high dose vitamin D therapies (i.e. 50,000 IU vitamin D).
  • Subjects with serum 25OH-VitD3 <10 ng/ml will be considered deficient and will be referred to their physician for treatment.
  • Subjects with serum 25OH-VitD3 >25 ng/ml.
  • Not able or willing to participate in 3-day-a-week monitored strength-training program.
  • Physician has placed a restriction on physical exercise.
Both
60 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00874575
MTI2008-CS01
Yes
Metabolic Technologies Inc.
Metabolic Technologies Inc.
  • Iowa State University
  • South Dakota State University
Principal Investigator: John A. Rathmacher, Ph.D. Metabolic Technologies
Metabolic Technologies Inc.
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP